Showing 2671-2680 of 9829 results for "".
Checkpoint Blockade for Advanced cSCC: Exploring Newer Options
https://practicaldermatology.com/topics/skin-cancer-photoprotection/checkpoint-blockade-for-advanced-cscc-exploring-newer-options/23487/Two newer systemic options on the market provide hope in the fight against advanced cutaneous squamous cell carcinoma.RIP Clarisonic, Hello New Contenders
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/rip-clarisonic-hello-new-contenders/23354/CSF faculty share top picks for at-home beauty devices.Management of Atopic Dermatitis During the COVID-19 Pandemic
https://practicaldermatology.com/topics/atopic-dermatitis/management-of-atopic-dermatitis-during-the-covid-19-pandemic/23322/There is concern about the immunosuppressive or immunomodulatory effects of oral and biologic medications in patients with skin disease.DermWireTV: AAD Virtual Data Highlights, Cynosure Consumer Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aad-virtual-data-highlights-cynosure-consumer-data/19818/The American Academy of Dermatology 2020 VMX Virtual Conference shines a light on fresh data from UCB, Leo Pharma, Lilly and Dermira, and Soliton. Cassiopea reports long-term data for Clascoterone. Zilxi from Menlo and Foamix approved for rosacea. Cynosure reports positive cosmetic consumer outlookFacing Challenges: Adapting Practice in the Face of COVID-19
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/facing-challenges-adapting-practice-in-the-face-of-covid-19/23266/CSF Faculty share experiences and tips for practicing in the “new normal.”DermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDA acIsotretinoin Updates 2019
https://practicaldermatology.com/topics/acne-rosacea/isotretinoin-updates-2019/23080/One of the best studied medications for treating acne, isotretinoin can deliver high rates of lasting cures with predictable side effect profiles. Here’s an update on the latest in patient management.Benefits and Challenges of Medical Practice Types
https://practicaldermatology.com/topics/practice-management/benefits-and-challenges-of-medical-practice-types/23058/As medicine in general and dermatology specifically shifts toward more employed physicians, it’s important to understand the options.Is Your Advisor Working in Your Best Interest?
https://practicaldermatology.com/topics/practice-management/is-your-advisor-working-in-your-best-interest/20361/Understanding fiduciary versus suitability standards.Inflammatory Responses: Managing Psoriasis in Light of Comorbidities
https://practicaldermatology.com/topics/psoriasis/inflammatory-responses-managing-psoriasis-in-light-of-comorbidities/20440/The accumulated evidence suggests that dermatologists must take an active role in addressing risks.